MeSH tree: N06.850.520.450
A large international study has found that asundexian, an investigational anti-clotting medication, reduces the risk of a stroke in people who recently experienced a stroke or transient ischemic attack (TIA) caused by a clot ...
Apr 15, 2026
0
76
Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live ...
Apr 14, 2026
0
25
A clinical trial led by University of Auckland researchers found that high-intensity therapy for patients begun within two weeks of a stroke did not improve hand and arm recovery beyond standard care. Targeting new treatments ...
Mar 26, 2026
0
2
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and can cause various types of cancer. Prophylactic HPV vaccination is highly effective and has been recommended in Switzerland since ...
Mar 25, 2026
0
3
An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; however, the latter firm's shares fell because the clinical trial did not reach its main goal.
Mar 23, 2026
0
7
Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical ...
Mar 19, 2026
0
19
Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).
Mar 12, 2026
0
6
In South Korea, postholiday weekdays are associated with a significantly increased incidence of out-of-hospital cardiac arrest, according to a study published online March 6 in JAMA Network Open.
Mar 11, 2026
0
3
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across multiple solid tumor types ...
Each year, tens of thousands of children under 5 die from diarrheal disease caused by enterotoxigenic Escherichia coli (ETEC), primarily in low-income countries. A new ETEC vaccine has shown promising results in reducing ...
Feb 18, 2026
0
6
